Medicenna Therapeutics Corp (MDNAF)

$0.67 -0.01 (-1.62%)
Market Cap 56.59M
Revenue (ttm) 0.00
Net Income (ttm) -8.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 32,948
Avg Vol 122,530
Day's Range N/A - N/A
Shares Out 83.41M
Stochastic %K 19%
Beta 1.84
Analysts Strong Sell
Price Target $2.99

Company Profile

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; MDNA209, an IL-2/IL-15...

Industry: Biotechnology
Sector: Healthcare
Phone: 416 648 5555
Address:
2 Bloor Street West, Suite 903 7th Floor, Toronto, Canada
Biosectors
Biosectors Jan. 7 at 8:31 PM
$MDNAF 113 has a long way to go probably 2 years but this NHP data may lead to some good science and studies from a toxicity, treatment combos like MDNA11 etc. we need continuous update on ability trials till May/June so matured data gets noticed by Big guys and street. Good results from Italian trials and update by sponsor every 8 weeks will be icing on cake that can potentially make noise and dent in melanoma space which is already proved but with BMS drug combo it may open doors for buy out. Merck is a perfect fit with so Much data and a billion is chump change for Merck for the 11, 55 and platform itself with best in class superkines. 2 years ago Sanofi blew away 2.5 billion on a third class IL and shelved it, will they acquire this now ?
0 · Reply
Spartrap
Spartrap Jan. 7 at 3:40 PM
$MDNAF MDNA113 NHP data coming very soon 🤞🏻🤞🏻🤞🏻
0 · Reply
boomshiva
boomshiva Jan. 2 at 2:37 PM
$MDNAF Tax loss selling is done and new positions being re/established?
1 · Reply
Lytnup
Lytnup Jan. 1 at 4:46 PM
$MDNAF An interesting recap of MDNA55, and some possible / probable next steps. https://open.substack.com/pub/davidbakke/p/back-to-the-future-of-mdna55-when?r=10wt7d&utm_medium=ios Looking forward to February’s Drug Development Summit https://glioblastoma-drugdevelopment.com
0 · Reply
Lytnup
Lytnup Dec. 31 at 1:32 PM
$MDNAF Some ight reading for all MDNAs on the last trading day of the year….. https://open.substack.com/pub/davidbakke/p/immune-governance-part-2?r=10wt7d&utm_medium=ios Here’s to more clinical data & validation -
0 · Reply
Biosectors
Biosectors Dec. 29 at 1:50 AM
$MDNAF Funding I am hoping and praying more matured Ability data in June with mdna113 in the mix even though a long way to go plus the Italian melanoma trial results with mdna11 combo Will pave way for Merck or BMS to consider a buy out. I still feel it’s a good fit for Merck considering they are doing combo trials since 18 months or so. Feel very optimistic about a big pharma and street exposure in first half of 2026. Good luck to all longs and happy new year.
1 · Reply
BigJon123
BigJon123 Dec. 26 at 11:21 PM
$MDNAF MDNA113 non-human data at the JP Morgan Healthcare Conference some time 12-15 Jan? ABILITY data in April? FDA approval for MDNA11 phase 2 vs Melanoma Apr - Jun? A lot of catalysts… hopefully one of them gets us the funding we need!
0 · Reply
AuriniaBeach
AuriniaBeach Dec. 25 at 11:43 PM
$MDNAF Hope all here have been spending quality time with their loved ones and are enjoying the Merriest of Christmases. J Coulborn over at BioPub has posted a brief but meaningful interview, conducted about a week ago, with Fahar Merchant. https://youtu.be/vPf-41e_mUM?si=-ylKK7S3sOjZR9Ny
1 · Reply
Biosectors
Biosectors Dec. 22 at 9:27 PM
$MDNAF Same here but don’t hate it yet just waiting 2 to 3 more quarters. This will turn around and a multi bagger. Yes patience wears out but not quitting at this finish line soon by August or September 2026 or may be a bit earlier too If nothing happens by September 2026 then it’s time to take a call. Good luck all longs Merry Christmas happy holidays and happy new year to all MDNAF folks
0 · Reply
Dipper2013
Dipper2013 Dec. 22 at 6:49 PM
$MDNAF ..such a pathetic chart... everyone from Nov, under water. Oh well..next!
0 · Reply
Latest News on MDNAF
No data available.
Biosectors
Biosectors Jan. 7 at 8:31 PM
$MDNAF 113 has a long way to go probably 2 years but this NHP data may lead to some good science and studies from a toxicity, treatment combos like MDNA11 etc. we need continuous update on ability trials till May/June so matured data gets noticed by Big guys and street. Good results from Italian trials and update by sponsor every 8 weeks will be icing on cake that can potentially make noise and dent in melanoma space which is already proved but with BMS drug combo it may open doors for buy out. Merck is a perfect fit with so Much data and a billion is chump change for Merck for the 11, 55 and platform itself with best in class superkines. 2 years ago Sanofi blew away 2.5 billion on a third class IL and shelved it, will they acquire this now ?
0 · Reply
Spartrap
Spartrap Jan. 7 at 3:40 PM
$MDNAF MDNA113 NHP data coming very soon 🤞🏻🤞🏻🤞🏻
0 · Reply
boomshiva
boomshiva Jan. 2 at 2:37 PM
$MDNAF Tax loss selling is done and new positions being re/established?
1 · Reply
Lytnup
Lytnup Jan. 1 at 4:46 PM
$MDNAF An interesting recap of MDNA55, and some possible / probable next steps. https://open.substack.com/pub/davidbakke/p/back-to-the-future-of-mdna55-when?r=10wt7d&utm_medium=ios Looking forward to February’s Drug Development Summit https://glioblastoma-drugdevelopment.com
0 · Reply
Lytnup
Lytnup Dec. 31 at 1:32 PM
$MDNAF Some ight reading for all MDNAs on the last trading day of the year….. https://open.substack.com/pub/davidbakke/p/immune-governance-part-2?r=10wt7d&utm_medium=ios Here’s to more clinical data & validation -
0 · Reply
Biosectors
Biosectors Dec. 29 at 1:50 AM
$MDNAF Funding I am hoping and praying more matured Ability data in June with mdna113 in the mix even though a long way to go plus the Italian melanoma trial results with mdna11 combo Will pave way for Merck or BMS to consider a buy out. I still feel it’s a good fit for Merck considering they are doing combo trials since 18 months or so. Feel very optimistic about a big pharma and street exposure in first half of 2026. Good luck to all longs and happy new year.
1 · Reply
BigJon123
BigJon123 Dec. 26 at 11:21 PM
$MDNAF MDNA113 non-human data at the JP Morgan Healthcare Conference some time 12-15 Jan? ABILITY data in April? FDA approval for MDNA11 phase 2 vs Melanoma Apr - Jun? A lot of catalysts… hopefully one of them gets us the funding we need!
0 · Reply
AuriniaBeach
AuriniaBeach Dec. 25 at 11:43 PM
$MDNAF Hope all here have been spending quality time with their loved ones and are enjoying the Merriest of Christmases. J Coulborn over at BioPub has posted a brief but meaningful interview, conducted about a week ago, with Fahar Merchant. https://youtu.be/vPf-41e_mUM?si=-ylKK7S3sOjZR9Ny
1 · Reply
Biosectors
Biosectors Dec. 22 at 9:27 PM
$MDNAF Same here but don’t hate it yet just waiting 2 to 3 more quarters. This will turn around and a multi bagger. Yes patience wears out but not quitting at this finish line soon by August or September 2026 or may be a bit earlier too If nothing happens by September 2026 then it’s time to take a call. Good luck all longs Merry Christmas happy holidays and happy new year to all MDNAF folks
0 · Reply
Dipper2013
Dipper2013 Dec. 22 at 6:49 PM
$MDNAF ..such a pathetic chart... everyone from Nov, under water. Oh well..next!
0 · Reply
boomshiva
boomshiva Dec. 22 at 6:40 PM
$MDNAF After almost 3 years in this ticker, I'm starting to hate it.
0 · Reply
Dipper2013
Dipper2013 Dec. 22 at 5:38 PM
$MDNAF no life here
1 · Reply
NewbJackCity
NewbJackCity Dec. 19 at 12:40 PM
$MDNAF interesting comment from Fahar yesterday about some sort of cap of 15 patients allowed per cancer type. So this explains the n=60 for mono and n=60 for combo. I don’t remember if this is some sort of protocol constraint or regulatory pathway?
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Dec. 19 at 5:34 AM
$MDNAF https://youtu.be/PpUdquhGbV0?si=ClSourMgFEmWapYH
1 · Reply
boomshiva
boomshiva Dec. 18 at 7:27 PM
$MDNAF Pretty much roundtripped since around Halloween. Ugh.
0 · Reply
smallinvestor
smallinvestor Dec. 17 at 6:08 PM
$MDNAF Never lost so much so fast on a stock….. on paper. Nothing to do but hold until this slaughter has past…..
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Dec. 17 at 2:27 PM
$MDNAF The entire article really speaks to MDNA and its mode of action and where else it can be used. Firstly the emphasis of priming of the immune system which that Dave guy on Substack lays out clearly and secondly when you look at all the other drugs mentioned… none work without healthy abundant T-Cells which in synergy MDNA would provide!!!
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Dec. 17 at 12:15 AM
$MDNAF Cancer World Dr Ascierto latest https://media.licdn.com/dms/document/media/v2/D4D1FAQEzxhsox09Q9g/feedshare-document-pdf-analyzed/B4DZsIbDGRLQAg-/0/1765372876832?e=1766620800&v=beta&t=VMUcRjpfa5zfJKgm0MABN2tip0hxrklXMYXpcvv5L0Y
1 · Reply
BigJon123
BigJon123 Dec. 16 at 8:01 PM
$MDNAF it’s a buy at $1.20, a buy at $0.80 and a buy at $0.60! We are sitting on a multi-bagger at all these levels with MDNA11, 55 and 113! ABILITY complete in 6-7 months, 113 primate data in 1 month, 55 partnership on the horizon!
2 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Dec. 16 at 7:53 PM
$MDNAF https://youtu.be/wCPxLWkPYjk
0 · Reply
boomshiva
boomshiva Dec. 16 at 7:36 PM
$MDNAF Added earlier today at 0.78XXX. If buying is good enough for management, it's good enough for me.
0 · Reply
Usmccbr
Usmccbr Dec. 16 at 10:54 AM
$MDNAF Watching with a finger on the buy button here…..bullish
0 · Reply